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Recent clinical trials have demonstrated the efficacy of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metasta-
tic non-small cell lung cancer. Most of these recent trials were conducted in patients with
EGFR mutation-positive tumors. As our knowledge of the EGFR mutation and its resistant
pathways develops, the complexity of the situation expands.This article briefly reviews the
pivotal trials leading to approval of EGFRTKIs in the first-line setting for patients with EGFR
mutation-positive non-small cell lung carcinomas. It discusses the historical use of EGFR
TKIs after the first-line setting in unselected patients and briefly describes ongoing trials.
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BACKGROUND
For many years, standard first-line systemic treatment for metasta-
tic NSCLC has consisted of chemotherapy with a two drug com-
bination including a platinum compound and a non-platinum
drug such as pemetrexed, gemcitabine, vinorelbine, or a taxane.
The typical median time to progression for chemotherapy-treated
patients is 4–6 months and median survival is 10–12 months. The
advent of epidermal growth factor receptor (EGFR) molecular
testing changed the treatment paradigm.
The EGFR or human epidermal growth factor receptor (HER)
family contains four members: EGFR (otherwise known as HER1),
HER2, HER 3, and HER4. In a normal cell, binding of the epider-
mal growth factor ligand causes dimerization, phosphorylation,
activation of the receptor, and triggering of signaling cascades
through pathways such as PI3-Kinase-AKT and RAS/RAF. The
presence of an EGFR gene mutation is activating, causing a con-
stant signal to be generated, which leads to cell proliferation and
other cancer processes.
Approximately 10–30% of NSCLC patients have an EGFR gene
mutation. This mutation is observed at a higher frequency in
some subpopulations. In Asian NSCLC cancer patients who never
smoked or were only light smokers, this percentage may be as high
as 60% (1). For NSCLC patients whose tumors test positive for any
EGFR mutations, an oral tyrosine kinase inhibitor (TKI) is now
the preferred first-line therapy.
FIRST-GENERATION EGFR TKIs
First-generation EGFR TKIs such as erlotinib and gefitinib
reversibly compete with adenosine triphosphate (ATP) binding
Abbreviations: ATP, adenosine triphosphate; CI, confidence interval; EGFR, epider-
mal growth factor receptor; HER, human epidermal growth factor receptor; HRQoL,
health-related quality of life; NCI, National Cancer Institute; NSCLC, non-small cell
lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free
survival; RCT, randomized clinical trial; TKI, tyrosine kinase inhibitor.
at the tyrosine kinase domain of EGFR. This inhibits ligand-
induced EGFR tyrosine phosphorylation, EGFR/HER1 activation,
and subsequent activation of the downstream signaling networks
(2). Pivotal randomized trials with these first-generation TKIs are
chronologically described in the sections below. Although it is
tempting to directly compare the results of these studies, a recent
publication (3) argues that this type of comparison is invalid due
to differences in trial design, comparator choice, and inclusion
criteria; readers are urged to refer to Sebastian et al.’s elegant
description and critical analysis of these trials (3).
IDEAL 1 AND IDEAL 2 – GEFITINIB PROVIDES A SURVIVAL ADVANTAGE
IN EGFR MUTATION-UNSELECTED PATIENTS
The IDEAL 1 (4) and IDEAL 2 (5) phase II trials were two of
the first studies to test gefitinib in patients with stage IV NSCLC.
These trials demonstrated that both 250 and 500 mg doses of gefi-
tinib were equally active in an EGFR mutation-unselected patient
population, resulting in response rates of approximately 20% and
median progression-free survival of 2.7 and 2.8 months for the
250 and 500 mg doses of gefitinib, respectively (4). Because both
doses showed equivalent results, the lower 250 mg dose was put
forward for the registration phase III trials. A subset of patients
treated with gefitinib demonstrated a very positive response, but
it was unclear why that was the case. At the time, the implications
of EGFR mutations were not understood, but we now know that
most of these patients likely harbored an EGFR gene mutation.
NCIC BR.21: ERLOTINIB FOR AN EGFR MUTATION-UNSELECTED
PATIENT POPULATION IMPROVES SURVIVAL
The NCIC BR.21 phase III trial demonstrated that erlotinib pro-
longed survival in NCSLC following the failure of first-line or
second-line chemotherapy (6). This multicenter, randomized con-
trol trial compared erlotinib to placebo in 731 patients with stage
IIIB/IV recurrent NSCLC. Study participants who had failed first-
or second-line chemotherapy were randomized 2:1 to receive
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either erlotinib or placebo. One half of the patients had received
one prior regimen, and half had received two prior regimens.
Patient selection was not based on EGFR mutation status, gender,
smoking history, or type of NSCLC.
This study met its primary endpoint of improving overall sur-
vival, 6.7 months for erlotinib compared to 4.7 months for placebo
(HR 0.70, CI 0.58–0.85, P < 0.001). The study demonstrated
statistically significant effects in secondary endpoints including
progression-free survival of 2.23 months for patients treated with
erlotinib compared to 1.84 months for those treated with placebo
(HR 0.61, CI 0.51–0.73, P < 0.001), time to symptom deterio-
ration, and response rate. Overall, 8.9% of patients achieved an
objective response to erlotinib (P < 0.001), although mutational
analysis was retrospective and only positive in approximately 40
patients. This trial demonstrated a survival benefit in all patients
regardless of whether their tumors had an EGFR gene mutation.
Why an EGFR inhibitor was efficacious in the absence of an
EGFR mutation is unclear. This reflects the complexity of the
EGFR mutation and other downstream signaling pathways, many
of which are still to be delineated. As a result of the NCIC BR.21
trial (6), erlotinib was approved and became standard of care in
the second or third line setting for patients with NSCLC.
ISEL: GEFITINIB PROVIDES NO SURVIVAL ADVANTAGE IN AN EGFR
MUTATION-UNSELECTED POPULATION
The Iressa Survival Evaluation in Lung Cancer (ISEL) phase III
study was similar to the NCIC BR.21 trial design as it compared
an EGFR TKI to placebo in EGFR mutation-unselected NSCLC
patients in the second and third line setting (7). Unlike NCIC
BR.21, this study failed to meet its endpoint of improved overall
survival, with median survival of 5.6 months for patients treated
with gefitinib as compared to 5.1 months for patients treated with
placebo (HR 0.89, CI 0.77–1.02, P = 0.087). There was a pro-
nounced heterogeneity in survival outcomes between groups of
patients, most notably those who were never smokers (HR 0.67,
CI 0.49–0.92, P = 0.012) and those of Asian ancestry (HR 0.66,
CI 0.48–0.91, P = 0.01). Due to the negative primary results of
this trial, gefitinib fell out of use for EGFR mutation-unselected
patients in North America.
DISCOVERY OF EGFR MUTATIONS
In 2004, two articles were published in prestigious journals by Paez
et al. (8) and Lynch et al. (9). Both publications demonstrated that
patients who responded well to gefitinib had EGFR gene muta-
tions, and the mutations were located in the region of the gene that
encoded the tyrosine kinase domain. Although much discussion
centered on whether the presence of the mutation should influ-
ence treatment decisions, clarity about the importance of EGFR
mutations did not occur until the Iressa Pan Asian Study (IPASS)
trial was completed, the mutation status of patients was analyzed,
and the biomarker story became clear.
IPASS TRIAL: GEFITINIB IMPROVES SURVIVAL IN THE FIRST LINE, IN
AN EGFR MUTATION-ENHANCED POPULATION
The IPASS trial was the study attributed to changing practice.
The goal of the IPASS trial was to evaluate the benefit of gefi-
tinib as compared to carboplatin/paclitaxel as first-line treatment
for patients with advanced NSCLC (10). Patients selected with
this trial had favorable clinical characteristics and included Asian
patients with adenocarcinoma, who were non-smokers or former
light smokers. Patients treated with gefitinib demonstrated supe-
rior progression-free survival as compared to those treated with
chemotherapy (HR 0.74, CI 0.65–0.85, P < 0.001).
An EGFR biomarker analysis was specified in this protocol,
but was retrospective and exploratory. Of 1200 patients, 437 had
a tumor specimen that was evaluable for EGFR mutation analy-
sis and of these, 261 patients (59.7%) had tumors that contained
EGFR gene mutations. In the subset of EGFR mutation-positive
patients, the response rate to gefitinib was 71.2% as compared to
47.3% for carboplatin/paclitaxel. PFS was significantly superior
for the EGFR mutation-positive patients treated with gefitinib,
9.5 months as compared to 6.3 months for those treated with
chemotherapy (HR 0.48,CI 0.36–0.64,P < 0.001). Overall survival
was not different, most likely due to crossover; 21.6 months for
gefitinib as compared to 21.9 months for carboplatin/paclitaxel.
Iressa Pan Asian Study demonstrated that an EGFR was the
most appropriate biomarker for the use of EGFR TKI inhibitors
in stage IV non-small cell lung carcinomas and with a significant
improvement in PFS and quality of life, gefitinib became standard
of care first-line option for NSCLC patients with EGFR-mutated
tumor. From this point onward, all TKI trials were conducted in
EGFR mutation selected populations and European authorities
restricted the use of gefitinib to patients with an EGFR mutation
only, regardless of therapeutic line.
WJOG AND NEJSG: JAPANESE TRIALS TESTING GEFITINIB IN EGFR
MUTATION SELECTED POPULATIONS
Two randomized phase III studies compared gefitinib to
chemotherapy in the first-line setting (11, 12). Both of these
trials, involving NSCLC patients selected on the basis of EGFR
mutations, demonstrated a statistically significant increase in
progression-free survival for patients treated with gefitinib over
chemotherapy. In the West Japan Oncology Group (WJOG) trial,
patients treated with gefitinib experienced a median PFS of 9.2
as compared to 6.3 months for those treated with chemotherapy
(HR= 0.489, CI 0.336–0.710,P < 0.0001) (11). Results were simi-
lar in the North-East Japan Study Group (NEJSG), where patients
treated with gefitinib experienced a median PFS of 10.8 months
compared to 5.4 months for those treated with chemotherapy
(HR= 0.30, CI 0.22–0.41,P < 0.001) (12). This study was stopped
following the results of a planned interim analysis as the gefitinib
arm had significantly superior PFS compared to the chemotherapy
arm. A high number of patients crossed over to gefitinib (98%);
this is the most likely explanation for no difference is overall
survival.
EURTAC TRIAL: ERLOTINIB IN THE FIRST-LINE IMPROVES
PROGRESSION-FREE SURVIVAL
The European Tarceva vs. Chemotherapy (EURTAC) trial was con-
ducted in patients with EGFR mutation positive tumors, and was
the first to demonstrate the benefits of an EGFR TKI in a Caucasian
population (13). Patients were randomized to receive erlotinib
or chemotherapy (cisplatin/gemcitabine or cisplatin/docetaxel)
in the first-line setting. Response rate was 58% in the erlotinib
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arm compared to 15% in the chemotherapy arm (P < 0.0001).
Progression-free survival was 9.7 months for patients treated with
erlotinib and 5.2 months for patients treated with chemotherapy
(HR= 0.37, CI 0.25–0.54, P < 0.0001) (13). Overall survival was
22.9 months in the erlotinib arm as compared to 18.8 months
in the chemotherapy arm (HR= 0.80; P = 0.42), most likely
confounded by second-line therapy and crossover to erlotinib.
SECOND-GENERATION TKIs
Afatinib and dacomitinib are second-generation EGFR TKIs, and
block all HER-family ligands, including HER1 (EGFR), as well as
HER2 and HER4. These agents form permanent covalent bonds
with the target, irreversibly inhibiting ATP binding at the tyrosine
kinase domain. As a result, second-generation TKIs are theo-
retically more effective in inhibiting EGFR signaling than first-
generation erlotinib or gefitinib because the inhibition of EGFR
signaling is prolonged for the entire lifespan of the drug-bound
receptor molecule (14).
Two phase III trials were conducted to test dacomitinib in
EGFR mutation-unselected populations. The Archer 1009 phase
III trial compared dacomitinib with erlotinib in EGFR mutation-
unselected patients who were previously treated with chemother-
apy. The trial did not demonstrate statistically significant improve-
ment in progression-free survival and was discontinued. The
NCIC BR.26 trial phase III trial compared dacomitinib with
placebo in 736 EGFR mutation-unselected patients with advanced
NSCLC previously treated with both chemotherapy and an EGFR
TKI. This study also did not meet its objective of prolonging over-
all survival. Subgroup analysis is currently being conducted in
order to understand if there was a difference in response between
patients whose tumors harbored an EGFR mutation and those
whose tumors did not.
A number of other trials testing the second-generation EGFR
TKI dacomitinib are underway and have yet to be published.
Archer 1050 is a phase III randomized, open-label trial comparing
dacomitinib to gefitinib in a first-line treatment setting in EGFR
mutation-positive NSCLC patients. In this trial, approximately 440
patients were randomized 1:1 to dacomitinib or gefitinib. The pri-
mary endpoint is PFS by independent review, while the secondary
endpoints include PFS by investigator assessment, overall survival,
best overall response, duration of response, safety and tolerability,
and patient-reported outcomes. As phase II studies of dacomitinib
in the first-line treatment setting were promising, we look forward
to the results of this phase III study, which will be revealed in
mid-2015.
AFATINIB FOR PATIENTS WITH EGFR MUTATION POSITIVE TUMORS
LUX-Lung 1 was a phase 2b/3 randomized trial comparing afa-
tinib to best supportive care in unselected patients who had
received both a platinum doublet and 3 months of an EGFR
TKI, gefitinib, or erlotinib (15). Although progression-free sur-
vival was increased, the primary endpoint of overall survival was
not. Because of this negative trial, the use of afatinib in patients
with an acquired resistance to EGFR TKIs was not approved in any
country except Japan.
The pivotal afatinib trial is LUX-Lung 3 (16). This phase III
trial randomized 345 patients with NSCLC in the first-line setting
who had EGFR mutation-positive tumors to receive either afa-
tinib or cisplatin/pemetrexed. For this study, all EGFR mutations
from codons 18–21 were analyzed. While the majority of patient
tumors harbored common EGFR mutations (Del-19 and Point
21 L858R), approximately 10% of patients had uncommon EGFR
mutations. The primary endpoint of this trial was progression-
free survival and secondary endpoints included overall survival,
objective response rate, and quality of life.
Afatinib treatment led to an increase in the objective response
rate compared with chemotherapy treatment (56.1 vs. 22.6%).
Patients randomized to afatinib experienced a significant improve-
ment in median progression-free survival compared with those
randomized to chemotherapy, 11.1 vs. 6.9 months, respectively
(HR 0.58, CI 0.43–0.78, P = 0.0004). The treatment effect of afa-
tinib was more pronounced when comparing progression-free
survival in the pre-defined subgroup of patients with the com-
mon Del-19 or Point 21 L858R EGFR mutations. In this subgroup,
patients treated with afatinib experienced progression-free sur-
vival of 13.6 months as compared to 6.9 months for those treated
with chemotherapy (HR 0.47, CI 0.34–0.65, P < 0.0001) (16).
The LUX-Lung 6 trial, conducted in Asia, confirmed the value
of afatinib in the population of patients with EGFR mutation-
positive tumors (17). This phase III, open-label trial random-
ized 364 NSCLC patients in a 2:1 fashion to receive afatinib
or gemcitabine/cisplatin. The primary endpoint in this study
was progression-free survival and secondary endpoints included
objective response rate, disease control rate, patient-reported
outcomes, and safety.
A statistically significant improvement in progression-free
survival was demonstrated between patients treated with afa-
tinib as compared to those treated with chemotherapy, 11.0
vs. 5.6 months, respectively (HR 0.28, CI 0.20–0.39, P < 0.0001)
(17). The progression-free survival benefit was consistent across
all subgroups, including all mutation categories. The percent-
age of LUX-Lung 6 patients with a confirmed objective response
was 67% in the afatinib group as compared to 23% in the
chemotherapy group. Overall, the results of the LUX-Lung 6
trial support the efficacy observations (progression-free survival
and objective response rate) demonstrated in the LUX-Lung
3 trial.
To date, none of the published randomized EGFR TKI tri-
als have demonstrated a statistically significant improvement in
overall survival. In the American Society of Clinical Oncology
meeting in Chicago 2014, a pooled analysis of LUX-Lung 3 and
LUX-Lung 6 was presented (18). Although the pooling of clinical
trial results in this way is controversial, the results are interest-
ing. According to this analysis, the overall survival of LUX-Lung
3 was 31.6 months for patients treated with afatinib as com-
pared to 28.2 months for those treated with chemotherapy (peme-
trexed/cisplatin) (HR: 0.78). The pooled overall survival analysis
of LUX-Lung 6 showed that patients treated with afatinib had
a median survival of 23.6 months as compared to 23.5 months
when treated with gemcitabine/cisplatin (HR 0.8). Although both
hazard ratios are approximately 0.8, neither of the P values were
significant.
The pooled analysis showed an important improvement
in overall survival in patients whose tumors had the most
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common EGFR mutations, Del-19 and Point 21 L858R. In the
sub-population of patients with these mutations, the median
overall survival in the afatinib arm was 27.3 months, which was sig-
nificantly improved over median overall survival of 24.3 months
in the chemotherapy arm (HR 0.81, p= 0.037).
The most interesting analysis concerned the subpopulation of
patients whose tumors had harbored the Del-19 deletion, where
a significant improvement in overall survival was seen in both
LUX-Lung 3 and LUX-Lung 6 trials. In the LUX-Lung 3 trail,
the median survival was 33.2 months for Del-19 patients treated
with afatinib as compared to 21.1 months with chemotherapy
(pemetrexed/cisplatin) (HR 0.54). In LUX-Lung 6, the median sur-
vival was 31.4 months for Del-19 patients treated with afatinib as
compared to 18.4 months for patients treated with chemotherapy
(gemcitabine/cisplatin) (HR 0.64). The author concluded that the
patients with Del-19 and Point 21 L858R mutations may constitute
very different populations, and may require different treatment
strategies (18).
A highly anticipated trial is LUX-Lung 7. This phase III, open-
label trial randomized 316 patients with EGFR mutation-positive
advanced adenocarcinoma to receive either afatinib or gefitinib.
The primary endpoint for the trial, which completed in July 2013,
was overall survival. We await the results eagerly.
Clinical trials with the third-generation EGFR TKIs are under-
way. These inhibitors work to selectively inhibit tumors that harbor
the acquired T790 mutation.
Currently, there are more than 350 open trials for EGFRs in
NSCLC, and at least 20 of these are phase III. Indeed, this is a very
exciting time in the evolution of our knowledge of the EGFR TKI
inhibitors, and we expect outstanding advances in the care of our
patients with non-small cell lung carcinoma.
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